What is HC Wainwright’s Estimate for ONCY FY2024 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Oncolytics Biotech in a report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.30) for the year, down from their previous estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.30) EPS, FY2027 earnings at ($0.29) EPS and FY2028 earnings at ($0.09) EPS.

A number of other brokerages also recently commented on ONCY. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Leede Financial cut Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th.

Oncolytics Biotech Price Performance

ONCY stock opened at $1.00 on Monday. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.75. The firm’s 50-day moving average is $1.09 and its 200 day moving average is $1.05. The company has a market capitalization of $76.69 million, a PE ratio of -3.69 and a beta of 1.69.

Institutional Investors Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC bought a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.